These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26469186)

  • 41. Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
    Avihingsanon A; Hughes MD; Salata R; Godfrey C; McCarthy C; Mugyenyi P; Hogg E; Gross R; Cardoso SW; Bukuru A; Makanga M; Badal-Aesen S; Mave V; Ndege BW; Fontain SN; Samaneka W; Secours R; Van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Munyanga C; Chagomerana M; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC; Grinsztejn B;
    J Int AIDS Soc; 2022 Jun; 25(6):e25905. PubMed ID: 36039892
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antidepressants for people with epilepsy and depression.
    Maguire MJ; Marson AG; Nevitt SJ
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD010682. PubMed ID: 33860531
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Behavioral and clinical characteristics of persons receiving medical care for HIV infection - Medical Monitoring Project, United States, 2009.
    Blair JM; Fagan JL; Frazier EL; Do A; Bradley H; Valverde EE; McNaghten A; Beer L; Zhang S; Huang P; Mattson CL; Freedman MS; Johnson CH; Sanders CC; Spruit-McGoff KE; Heffelfinger JD; Skarbinski J;
    MMWR Suppl; 2014 Jun; 63(5):1-22. PubMed ID: 24941443
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-persistence to antiretroviral therapy among adults receiving HIV medical care in the United States.
    Nyaku M; Beer L; Shu F
    AIDS Care; 2019 May; 31(5):599-608. PubMed ID: 30309269
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon.
    Aghokeng AF; Kouanfack C; Eymard-Duvernay S; Butel C; Edoul GE; Laurent C; Koulla-Shiro S; Delaporte E; Mpoudi-Ngole E; Peeters M
    J Int AIDS Soc; 2013 Jan; 16(1):18004. PubMed ID: 23374858
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial.
    Laurent C; Kouanfack C; Laborde-Balen G; Aghokeng AF; Mbougua JB; Boyer S; Carrieri MP; Mben JM; Dontsop M; Kazé S; Molinari N; Bourgeois A; Mpoudi-Ngolé E; Spire B; Koulla-Shiro S; Delaporte E;
    Lancet Infect Dis; 2011 Nov; 11(11):825-33. PubMed ID: 21831714
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiretroviral therapy programme outcomes at Senkatana antiretroviral therapy clinic, Lesotho: a four-year retrospective cohort study.
    Kabuya M; Musekiwa A; Takuva S; Thabane L; Mbuagbaw L
    Pan Afr Med J; 2023; 46():74. PubMed ID: 38282767
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study.
    Kiweewa F; Esber A; Musingye E; Reed D; Crowell TA; Cham F; Semwogerere M; Namagembe R; Nambuya A; Kafeero C; Tindikahwa A; Eller LA; Millard M; Gelderblom HC; Keshinro B; Adamu Y; Maswai J; Owuoth J; Sing'oei VC; Maganga L; Bahemana E; Khamadi S; Robb ML; Ake JA; Polyak CS; Kibuuka H
    PLoS One; 2019; 14(2):e0211344. PubMed ID: 30721233
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Virologic and immunologic impact and durability of enfuvirtide-based antiretroviral therapy in HIV-infected treatment-experienced patients in a clinical setting.
    Loutfy MR; Antoniou T; Shen S; Diong C; Vlaicu M; Halpenny R; Kovacs C; Fletcher D; Raboud JM
    HIV Clin Trials; 2007; 8(1):36-44. PubMed ID: 17434847
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Virological profile of pregnant HIV positive women with high levels of CD4 count in low income settings: can viral load help as eligibility criteria for maternal triple ARV prophylaxis (WHO 2010 option B)?
    Njom Nlend AE; Same Ekobo C; Moyo ST; Nguetcheng GC; Ngang P; Lyeb S; Meka L; Baane M
    Pan Afr Med J; 2011; 10():27. PubMed ID: 22187609
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence and predictors of major depression in HIV-infected patients on antiretroviral therapy in Bamenda, a semi-urban center in Cameroon.
    Gaynes BN; Pence BW; Atashili J; O'Donnell J; Kats D; Ndumbe PM
    PLoS One; 2012; 7(7):e41699. PubMed ID: 22860006
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance.
    Salata RA; Grinsztejn B; Ritz J; Collier AC; Hogg E; Gross R; Godfrey C; Kumarasamy N; Kanyama C; Mellors JW; Wallis CL; Hughes MD;
    AIDS Res Ther; 2023 Jan; 20(1):3. PubMed ID: 36604746
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Coping Strategies and Symptoms of Mental Health Disorders Among People with HIV Initiating HIV Care in Cameroon.
    Parcesepe AM; Filiatreau LM; Gomez A; Ebasone PV; Dzudie A; Pence BW; Wainberg M; Yotebieng M; Anastos K; Pefura-Yone E; Nsame D; Ajeh R; Nash D
    AIDS Behav; 2023 Jul; 27(7):2360-2369. PubMed ID: 36609704
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association between race, depression, and antiretroviral therapy adherence in a low-income population with HIV infection.
    Kong MC; Nahata MC; Lacombe VA; Seiber EE; Balkrishnan R
    J Gen Intern Med; 2012 Sep; 27(9):1159-64. PubMed ID: 22528619
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Collaborative care for the detection and management of depression among adults receiving antiretroviral therapy in South Africa: study protocol for the CobALT randomised controlled trial.
    Fairall L; Petersen I; Zani B; Folb N; Georgeu-Pepper D; Selohilwe O; Petrus R; Mntambo N; Bhana A; Lombard C; Bachmann M; Lund C; Hanass-Hancock J; Chisholm D; McCrone P; Carmona S; Gaziano T; Levitt N; Kathree T; Thornicroft G;
    Trials; 2018 Mar; 19(1):193. PubMed ID: 29566739
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The association between a detectable HIV viral load and non-communicable diseases comorbidity in HIV positive adults on antiretroviral therapy in Western Cape, South Africa.
    George S; McGrath N; Oni T
    BMC Infect Dis; 2019 Apr; 19(1):348. PubMed ID: 31029087
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (ANRS 12288 EVOLCAM).
    Liégeois F; Eymard-Duvernay S; Boyer S; Maradan G; Kouanfack C; Domyeum J; Boyer V; Mpoudi-Ngolé E; Spire B; Delaporte E; Vidal L; Kuaban C; Laurent C;
    HIV Med; 2019 Jan; 20(1):38-46. PubMed ID: 30362279
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improving adherence and clinical outcomes through an HIV pharmacist's interventions.
    Ma A; Chen DM; Chau FM; Saberi P
    AIDS Care; 2010 Oct; 22(10):1189-94. PubMed ID: 20640958
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thrombocytopenia according to antiretroviral drug combinations, viremia and CD4 lymphocytes among HIV-infected patients in Cameroon: a snapshot from the City of Yaoundé.
    Nka AD; Sosso SM; Fokam J; Bouba Y; Teto G; Simo Rachel R; Tiga A; Yimga J; Nukenine EN; Nanfack AJ; Takou D; Aroga Z; Colizzi V; Ndjolo A
    BMC Res Notes; 2019 Sep; 12(1):632. PubMed ID: 31554515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.